Company
A platform company, not a supplement brand.
Jowin Inc. has spent more than 12 years combining prevention products with medical validation, hospital networks, insurance linkage, and patent protection — so prevention can finally be a trusted, sustainable category.
What we are
A global preventive-healthcare platform.
Jowin connects prevention products, medical professionals, validation systems, and insurance structures into one licensable model.
The point is not to sell better supplements. The point is to change how the prevention market works — by making products verifiable, by tying them to insurance benefits, and by giving country-level partners a complete, ready-to-localize system.
What we are not
Not a direct-to-consumer brand.
We are not a brand competing on packaging or marketing spend. We are not a single-product company. We do not export shipping containers of bottles.
We license a model — patents, formulas, ingredient supply, insurance-linked structure, and brand usage — to one partner per country, who runs it locally.
Corporate basics
Jowin Inc. — at a glance.
Patent: HealthInsu™ business-model registration · HQ: Republic of Korea
Validated in Korea
The numbers behind the model.
Why Jowin
Six things you get on day one.
Prevention R&D
Disease-specific prevention formulas, key ingredient supply chains, and clinical-grade validation logic — built up over more than a decade.
Patent protection
The HealthInsu™ model is protected by business-model patents and system patents, layered to defend across jurisdictions.
Validation in market
Hyundai Accounting valuation of ≈ USD 900M. Sold-out launch of the cancer-prevention product. Local-government discussions underway.
Hospital + insurer + maker
Specialty hospitals, supplement manufacturers, insurers, and marketing partners — already wired into the same model.
HiClinic companies
HiEyes, HiDental, HiJoint — separate verticals built with specialist physicians, each on its own path to independent growth.
Platform trajectory
Near-term: country-level licensing and an IPO. Long-term: an own-platform play in global preventive insurance.
Korean reference points
The references behind the valuation.
≈ USD 900M
Independent valuation of the HealthInsu™ model by Hyundai Accounting Corporation (KRW 1.3 trillion).
Cancer-prevention product sold out
Jowin's first cancer-prevention product sold out after launch — an early demand signal for the validated-prevention category.
Seoul eye-health partnerships
Specialty eye clinics in Seoul have introduced eye-health supplements connected to the HealthInsu™ model.
Local-government adoption talks
Korean local governments are exploring the HealthInsu™ system for senior-citizen healthcare programs.
Hyundai Marine & Fire
Active partnership discussions to develop prevention-linked insurance products.
Patent layering
Multi-layer business-model and system patents in Korea, with additional applications and global filings underway.
The roadmap
From Korean validation to global platform — in six stages.
-
Stage 1 · Consolidate
The Korean model
Launch Jowin's own channels, structure the domestic licensing pipeline, validate HiClinic verticals, stabilize the trial program.
-
Stage 2 · Expand
10-country licensing
Identify, qualify, and contract country-level licensing partners in 10 priority markets — each running a fully localized HealthInsu™ business.
-
Stage 3 · IPO
Jowin public listing
Validated by 10-country traction, Jowin pursues a public listing. Indicative target enterprise value: ≈ USD 1.05B at IPO.
-
Stage 4 · Verticals
HiClinic specialty companies
HiEyes, HiDental, HiJoint, women's-health verticals, oncology — each spun out as an independent specialty company on its own growth and listing path.
-
Stage 5 · Platform
Global preventive-insurance platform
From insurer partnerships to an own-platform play in global preventive insurance — the long-horizon objective beyond licensing.
-
Stage 6 · Scale
100 countries and beyond
From 10 priority markets to a global footprint, supported by sub-licensing structures in each region.
Forward-looking statements describe internal targets and structural intent, not guarantees. All long-term licensing, valuation, and IPO terms are subject to separate agreement and regulatory review.